Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis (Q83661349)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 18, 2011

Language	Label	Description	Also known as
English	Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis	scientific article published on March 18, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

multiple sclerosis

1 reference

based on heuristic

inferred from title

Ernie Willoughby

6

object named as

Ernie Willoughby

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Gavin Giovannoni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

William Aschenbach

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Amy Pace

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Robert Hyde

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

J. Theodore Phillips

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21421809

27 November 2024

Fred D. Lublin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21421809

27 November 2024

Paul W. O'Connor

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21421809

27 November 2024

Chris H. Polman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21421809

27 November 2024

Frederick E. Munschauer

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21421809

27 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21421809

27 November 2024

publication date

18 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

full work available at URL

https://journals.sagepub.com/doi/pdf/10.1177/1352458511399611

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

https://journals.sagepub.com/doi/full-xml/10.1177/1352458511399611

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

970-979

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

2

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

3

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

4

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

5

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

6

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Health-related quality of life in multiple sclerosis: effects of natalizumab

7

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

8

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

9

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Contribution of relapses to disability in multiple sclerosis

10

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Effect of relapses on development of residual deficit in multiple sclerosis

11

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Impact of multiple sclerosis relapses on progression diminishes with time

12

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis

13

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Promotion of endogeneous remyelination in Multiple Sclerosis

14

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells

15

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis

16

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Spontaneous remyelination following prolonged inhibition of alpha4 integrin in chronic EAE

18

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Disability as an outcome in MS clinical trials

19

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up

20

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

21

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

22

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

23

1 reference

10.1177/1352458511399611

https://api.crossref.org/works/10.1177/1352458511399611

27 November 2024

Identifiers

10.1177/1352458511399611

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21421809%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83661349&oldid=2281739172"